Recombinant III-type collagen Yves-Cl3 with anti-aging effect as well as preparation method and application of recombinant III-type collagen Yves-Cl3
Through the expression and purification of recombinant type III collagen Yves-Col3, the problem of collagen sequence utilization was solved, and its significant effects in cell proliferation, free radical scavenging and anti-inflammatory were achieved, and the synthesis of type III collagen was promoted and the synthesis of type III collagen was delayed. Skin aging.
Patent Information
- Application Number
- CN202411092910.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-09
AI Technical Summary
The prior art is difficult to effectively utilize the sequence of collagen, resulting in its anti-aging, anti-inflammatory and pro-collagen regeneration effects not being widely used, and the loss of collagen leads to skin aging.
Using recombinant type III collagen Yves-Col3, its amino acid sequence is shown in SEQ ID NO.1 or SEQ ID NO.2, it is expressed and purified in host bacteria by constructing expression vectors, which is used to promote cell proliferation, scavenging free radicals and Anti-inflammatory, promoting the in vitro synthesis of type III collagen.
Recombinant type III collagen Yves-Col3 is not cytotoxic, has high thermal stability, significantly eliminates hydroxyl radicals and DPPH radicals, promotes cell proliferation, has significant anti-aging effects, and can be used to prepare anti-inflammatory agents and promotes type III collagen. Protein synthesis.
Smart Images

Figure CN118909094A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a recombinant type III collagen Yves-Col3 with anti-aging effect and a preparation method and application thereof, belonging to the technical field of protein expression. Background Art
[0002] Collagen is a high-grade protein whose molecules are composed of a variety of amino acids, including proline, glycine, etc. Its unique biological activity is built on the three-dimensional structure of triple superhelix. As the most abundant and widely distributed protein in the human body, collagen builds a tough support structure in the skin, bones and connective tissues, and is closely related to key processes such as maintaining the youthful state of the skin, wound healing and cell regeneration. Adult skin is mainly rich in type I collagen, while infant skin is mainly rich in type III collagen, which gives the skin delicateness and elasticity. However, with age, the body's ability to synthesize type III collagen decreases, and the loss of collagen accelerates, causing signs of skin aging.
[0003] Aging is a physiological process that occurs naturally and cannot be avoided in organisms. Aging is usually accompanied by a chronic, low-grade, systemic inflammation, which involves the activation of inflammatory networks and the release of related cytokines, including key pro-inflammatory mediators such as TNF-α, IL-6, and IL-1β. This process is an important driving force for inducing aging and aging-related diseases. As a complex physiological mechanism, there are currently free radical theory, damage theory, genetic theory, immune theory, telomere theory, etc. The free radical theory of aging proposed by Denham Harman in 1956 believes that the degenerative changes in the aging process are caused by the harmful effects of free radicals produced during normal cell metabolism. The free radicals mentioned here are mainly oxygen free radicals, such as superoxide anion free radicals, lipid oxygen free radicals, hydroxyl free radicals, nitrogen dioxide and nitric oxide free radicals. Maintaining an appropriate level of antioxidants and free radical scavengers in the body can prolong life and delay aging.
[0004] More and more studies have shown that collagen may have anti-aging, anti-inflammatory and collagen regeneration effects. However, this requires in-depth analysis of the collagen sequence to obtain the appropriate sequence to effectively exert the corresponding effects, resulting in no suitable collagen being widely used. Summary of the invention
[0005] The purpose of the present invention is to provide a recombinant type III collagen Yves-Col3 with anti-aging effect.
[0006] The technical solution adopted by the present invention is:
[0007] A recombinant type III collagen Yves-Col3 with anti-aging effect, whose amino acid sequence is shown in SEQ ID NO.1 or SEQ ID NO.2.
[0008] The gene encoding the aforementioned recombinant type III collagen Yves-Col3.
[0009] Preferably, the nucleotide sequence is shown as SEQ ID NO.3 or SEQ ID NO.4.
[0010] The aforementioned expression vector of recombinant type III collagen Yves-Col3.
[0011] The host bacteria of the aforementioned recombinant type III collagen Yves-Col3.
[0012] The aforementioned method for preparing the recombinant type III collagen Yves-Col3 comprises the following steps:
[0013] (1) constructing the aforementioned expression vector and transforming it into an expression host bacterium;
[0014] (2) Cultivating the expression host bacteria and inducing the expression of the recombinant protein;
[0015] (3) Purify the expression product to obtain the aforementioned recombinant type III collagen Yves-Col3.
[0016] The application of the aforementioned recombinant type III collagen Yves-Col3 in promoting cell proliferation in vitro.
[0017] Preferably, the cells are human fibroblasts.
[0018] The aforementioned recombinant type III collagen Yves-Col3 is used for scavenging free radicals or superoxide anions in vitro.
[0019] The use of the aforementioned recombinant type III collagen Yves-Col3 in the preparation of anti-inflammatory agents.
[0020] The use of the aforementioned recombinant type III collagen Yves-Col3 in promoting the in vitro synthesis of type III collagen.
[0021] Beneficial effects of the present invention:
[0022] The recombinant type III collagen Yves-Col3 of the present invention can be expressed by prokaryotic fermentation, has no cytotoxicity, has high thermal stability, can significantly remove hydroxyl free radicals and DPPH free radicals, promotes cell proliferation, has significant anti-aging effects, and can be compounded with other proteins to become raw materials for tissue engineering products, cosmetics, health products or medicines. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 The expression vector map of the recombinant type III collagen Yves-Col3 of the present invention.
[0024] Figure 2 Purification SDS-PAGE diagram of the recombinant type III collagen Yves-Col3 of the present invention, lane 1: supernatant of Yves-Col3-A3 after heating at 70°C for 1 hour, lane 2: Yves-Col3-A3 after purification by ion exchange column, lane 3: supernatant of Yves-Col3-A6 after heating at 70°C for 1 hour, lane 2: Yves-Col3-A6 after purification by ion exchange column.
[0025] Figure 3 Cell proliferation experiment of the recombinant type III collagen Yves-Col3 of the present invention.
[0026] Figure 4 The recombinant type III collagen Yves-Col3 of the present invention is tested for scavenging hydroxyl free radicals and DPPH free radicals.
[0027] Figure 5 The anti-inflammatory efficacy test of the recombinant type III collagen Yves-Col3 of the present invention.
[0028] Figure 6 Experiment on promoting collagen synthesis of fibroblasts by the recombinant type III collagen Yves-Col3 of the present invention. DETAILED DESCRIPTION
[0029] The present invention is further illustrated by examples below, but is not intended to be limiting of the present invention. The specific materials used in the embodiments of the present invention and their sources are provided below. However, it should be understood that these are merely exemplary and are not intended to limit the present invention, and materials identical or similar to the types, models, qualities, properties or functions of the following reagents and instruments can be used to implement the present invention. The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.
[0030] Example 1: Preparation of recombinant type III collagen Yves-Col3 plasmids
[0031] (1) Gene design and synthesis
[0032] In the present invention, an expression vector of recombinant type III collagen Yves-Col3 is constructed, wherein the recombinant type III collagen Yves-Col3 is respectively Yves-Col3-A3 and Yves-Col3-A6, whose corresponding amino acid sequences are respectively shown in SEQ ID No.1 and SEQ ID No.2, and whose nucleotide sequences are respectively shown in SEQ ID No.3 and SEQ ID No.4. The nucleotide sequences SEQ ID No.3 and SEQ ID No.4 are entrusted to Beijing Liuhe BGI Genomics Technology Co., Ltd. for synthesis.
[0033] (2) Construction of recombinant expression vector
[0034] The above-synthesized gene fragment was used as a template for PCR amplification, and the target gene fragment and the pET30a expression vector backbone were connected by Gibson-plasmid connection to obtain the corresponding plasmid.
[0035] Primer design:
[0036]
[0037] PCR amplification system:
[0038] System components Ingredient volume Primer F 2.5μL Primer R 2.5μL Q5 High-Fidelity 2x Master Mix 2μL Encoding genes commissioned by BGI to be synthesized 25μL <![CDATA[ddH 2 The]]> To 50μL
[0039] After the PCR system was prepared, it was mixed and centrifuged. The PCR amplification conditions were as follows: the first stage was pre-denaturation at 98°C for 30s; the second stage was denaturation at 98°C for 10s, annealing at 50-72°C for 30s, extension at 72°C for 30s / kb, and 32 cycles; the third stage was final extension at 72°C for 2min. The above vector or gene fragment was recovered using a universal DNA purification kit (Tiangen Biochemical Technology Co., Ltd.) and the operation steps in the product manual were followed.
[0040] Gibson Connection:
[0041] System components Ingredient volume Gibson Assembly Master Mix(2X) 5μL Connect fragments 0.2–1pmols*XμL <![CDATA[dd H 2 The]]> (5-X)μL Overall system 10μL
[0042] After mixing the above components on ice, place in a 37°C heat bath for 60 min. The obtained ligation product is stored on ice or at -20°C for subsequent competent cell transformation.
[0043] The ligation product was transformed into the host bacteria E. coli DH5α by the heat shock method, spread on LB culture resistance plates, and incubated at 37°C overnight. Positive clones were randomly picked and inoculated into LB liquid culture medium, and cultured at 37°C, 220rpm overnight. The plasmid was extracted using a plasmid rapid extraction kit, and the successfully constructed plasmids were named pET30a-C3-A3 and pET30a-C3-A6, respectively.
[0044] (3) Construction of engineered bacteria
[0045] The recombinant expression plasmid obtained above was transferred into the competent E. coli cells BL21 (DE3) by heat shock, and positive E. coli genetically engineered bacteria were screened. The specific process was as follows: ① 4 μL of the recombinant expression plasmid was added to 100 μL of the competent E. coli cells BL21 (DE3), and the mixture was placed on ice for 30 min; ② the mixture was heat shocked in a 42°C water bath for 90 s, and then quickly placed on ice for 2 min; ③ 700 μL of non-resistant LB liquid medium (10 g / L peptone, 5 g / L yeast extract) was added to the mixture. , 10 g / L sodium chloride), 37°C, 220 rpm for 1 h; ④ Take 200 μL of the bacterial solution and evenly spread it on an LB solid culture medium plate containing ampicillin (10 g / L peptone, 5 g / L yeast extract, 10 g / L sodium chloride, 15 g / L agar, 100 μg / mL ampicillin); ⑤ Incubate the plate upside down in a 37°C incubator for about 16 h, and wait for clearly visible colonies to grow, thereby obtaining the corresponding DE3-pET30a-C3-A3 and DE3-pET30a-C3-A6 engineered bacteria.
[0046] Example 2: Induced expression of engineered bacteria
[0047] The single colony on the plate was placed in LB liquid medium containing ampicillin, and cultured at 37°C, 220rpm for 10 hours. This was the primary seed solution, which was inoculated into a new LB medium at a 1% inoculum and cultured at 37°C overnight. It was inoculated into a new LB medium at a 5% inoculum and cultured at 37°C for 2 hours. IPTG with a final concentration of 0.5mM was added at 18°C for induction expression and cultured for 16 hours. The bacteria were collected by centrifugation at 4000g and 4°C for 20 minutes.
[0048] The cells were resuspended in lysis buffer (20 mM Tris-HCl, 1 mM EDTA, 500 mM NaCl, pH 8.5), 100X protease inhibitor PMSF was added, high shear dispersing emulsifier was used to disperse the cells, high pressure homogenizer was used, 800-1000 bar, homogenization was performed for 15-30 min, after the cells were broken, 1 mL of the broken liquid was taken and centrifuged at 4 ° C and 12000 rpm for 2 min, 80 μL of the supernatant was taken, the precipitate was resuspended with 200 μL of lysis buffer, 120 μL of the resuspension was discarded, 20 μL of 5X protein loading buffer was added to the supernatant and the precipitate, the mixture was heated in a boiling water bath for 10 min for SDS-PAGE, and protein expression was confirmed.
[0049] Example 3: Purification of expression products
[0050] The supernatant of the crushed liquid obtained in Example 2 was heated in a 70°C water bath for 1 h to remove most of the impurities. The protein solution after heating was cooled to room temperature and centrifuged at 4°C and 12000 rpm for 20 min. The supernatant was taken and the precipitate was discarded. 80 μL of the supernatant was added with 20 μL of 5X protein loading buffer, mixed and heated in a boiling water bath for 10 min for SDS-PAGE, and grayscale analysis gel images were made using imagej software. The protein yield and purity are shown in the following table:
[0051]
[0052]
[0053] As shown in the above table, Yves-Col3-A3 and Yves-Col3-A6 have high yields and good thermal stability. The supernatant protein solutions of Yves-Col3-A3 and Yves-Col3-A6 were enriched and purified by positive ion exchange resin, and the purified Yves-Col3-A3 and Yves-Col3-A6 proteins were collected. 80 μL of supernatant was added with 20 μL of 5X protein loading buffer, and the mixture was heated in a boiling water bath for 10 min for SDS-PAGE. Imagej software was used to make grayscale analysis gel images. The protein yield and purity are shown in the following table:
[0054] protein Yield mg / L purity% Yves-Col3-A3 350 99 Yves-Col3-A6 380 99
[0055] The purification results of Yves-Col3-A3 and Yves-Col3-A6 are shown in Figure 2 As shown, the purified protein band is single and has high purity.
[0056] Example 4: Detection of biological activity of recombinant type III humanized collagen Yves-Col3
[0057] (1) Cell proliferation experiment with recombinant type III collagen Yves-Col3
[0058] The MTT cell proliferation detection kit was used to detect the effects of the recombinant type III collagen Yves-Col3-A3 and Yves-Col3-A6 prepared in Example 3 on the proliferation of fibroblast HFF-1. The specific detection steps can be routinely adjusted according to the kit instructions, wherein the control group is DMEM complete medium, the experimental groups 1-3 are DMEM complete medium containing 1, 10, 100 ng / mL Yves-Col3-A3 or Yves-Col3-A6, respectively, and the positive control group is DMEM complete medium containing 100 ng / mL TGF-β1. The cell dosage of each group is 1×10 4 indivual.
[0059] Test results such as Figure 3 As shown, 10 ng / mL of recombinant type III collagen Yves-Col3-A3 and Yves-Col3-A6 can effectively promote the proliferation of fibroblasts, and there is a dose effect, and the larger the dose, the more significant the growth promotion of fibroblasts. It is confirmed that the recombinant type III collagen Yves-Col3-A3 and Yves-Col3-A6 of the present invention have the effect of promoting the growth of fibroblasts.
[0060] (2) Experiments on the scavenging of hydroxyl radicals, DPPH radicals and superoxide anions by recombinant type III collagen Yves-Col3
[0061] Determination of DPPH free radical scavenging ability: Take a test tube, add 2mL of sample solution, then add 2.5mL of 0.1mmol / L DPPH solution to each test tube, shake well and place at room temperature in the dark for 30 minutes, centrifuge and take the supernatant to measure the absorbance at 517nm. The scavenging rate is calculated as follows:
[0062] Clearance rate (%) = [1-(A 1 -A 2 ) / A 0 ]×100%
[0063] In the formula, A 0 is the absorbance of the sample solution replaced by distilled water; A 1 A is the absorbance after adding sample solution; 2 is the absorbance of the DPPH solution replaced by distilled water.
[0064] Determination of hydroxyl radical scavenging ability: Take a test tube, first add 2mL of 8mmol / L ferrous sulfate solution, then add 2mL of 8mmol / L salicylic acid-ethanol solution, then add 2mL of sample solution, and finally add 1mL of 0.03% hydrogen peroxide to start the reaction, shake well, let stand at room temperature for 20 minutes, centrifuge and take the supernatant to measure the absorbance value at 510nm. The scavenging rate calculation formula is as follows:
[0065] Clearance rate (%) = [1-(A 1 -A 2 ) / A 0 ]×100%
[0066] In the formula, A 0 is the absorbance of the sample solution replaced by distilled water; A 1 A is the absorbance after adding sample solution; 2 The absorbance of the salicylic acid-ethanol solution was replaced by distilled water.
[0067] Determination of superoxide anion scavenging ability: Take test tubes and add 4.5mL of Tris-HCl buffer solution with pH=8.2, and react in a 30℃ water bath for 10min. Then add 0.5mL of sample solution and 1mL of 45mmol / L pyrogallol solution, mix well, and then stir and react in a 30℃ water bath for 5min. Immediately after the water bath, terminate the reaction with 6mol / L concentrated hydrochloric acid, and measure the absorbance value of the supernatant at 325nm. The scavenging rate is calculated as follows:
[0068] Clearance rate (%) = [1-(A 1 -A 2 ) / A 0 ]×100%
[0069] In the formula, A 0 is the absorbance of the sample solution replaced by distilled water; A 1 A is the absorbance after adding sample solution; 2 The absorbance of the pyrogallol solution was replaced by distilled water.
[0070] The results are as follows Figure 4 As shown, both recombinant type III collagen Yves-Col3-A3 and Yves-Col3-A6 have significant free radical scavenging effects, among which Yves-Col3-A6 protein has better effect and has good anti-aging effect.
[0071] (3) Anti-inflammatory efficacy experiment of recombinant type III collagen Yves-Col3
[0072] Experimental principle: During skin inflammation, many inflammatory factors are secreted, such as tumor necrosis factor-α (TNF-α). When the inflammation is relieved, the inflammatory factors will also decrease. This experiment uses UVB (irradiation dose of 300mJ / cm 2 , irradiation time 228s) to stimulate human keratinocytes to construct an inflammation model and make the cells secrete inflammatory factors. The cells were then treated with recombinant type III collagen Yves-Col3, and the expression of TNF-α in the supernatant was quantitatively detected by ELISA to investigate whether recombinant type III collagen Yves-Col3 has an inhibitory effect on the release of TNF-α, thereby achieving an anti-inflammatory effect.
[0073] The basic principle of ELISA is to use the specific reaction principle of antigen and antibody. After the antigen or antibody is solidified and the antigen or antibody is enzyme-labeled, the substrate of the enzyme reaction is added, and the substrate is catalyzed by the enzyme to become a colored product. The amount of the product is directly related to the amount of TNF-α in the supernatant. The ELISA experiment can convert chemical signals into electrical signals, and TNF-α can be quantitatively analyzed by detecting the OD value with an enzyme marker.
[0074] Dexamethasone can inhibit the release of cytokines, thereby reducing inflammatory and immune responses. The mechanism of action of dexamethasone is mainly to exert its anti-inflammatory, anti-allergic and immunosuppressive effects by affecting the intracellular signal transduction pathway. It can inhibit the synthesis of inflammatory mediators, inhibit the migration and infiltration of inflammatory cells, inhibit the activation and proliferation of immune cells, inhibit the release of cytokines, etc. It is used as a reference control in this experiment.
[0075] Experimental steps: The experimental design is shown in the following table. The ELISA kit in the table is a kit for measuring Human TNF-α.
[0076] Anti-inflammatory experimental design
[0077]
[0078]
[0079] Experimental method: After digestion, cells in logarithmic growth phase were inoculated into 6-well plates at a certain inoculation density at 37°C and 5% CO. 2 Incubate overnight in an incubator; treat when the cell plating rate in the 6-well plate reaches 50%. The blank group and the stimulation group do not need to be treated. The reference control group is treated with 0.01% dexamethasone, and the experimental group is treated with 0.1% Yves-Col3-A3 or Yves-Col3-A6. Each group has 3 replicates. After treatment, 37°C, 5% CO 2 The cells were cultured in the incubator for 24 h. Except for the blank group, the other groups were irradiated with UVB (irradiation dose of 300 mJ / cm 2 After that, the experimental group and the control group were replaced with normal culture medium at 37°C and 5% CO 2 After 24 hours of continuous culture, the supernatant was collected and the secretion of TNF-a was detected and analyzed using an ELISA kit.
[0080] The results are as follows Figure 5 As shown, the secretion of inflammatory factor TNF-a in the stimulation group increased significantly compared with the blank group, indicating that UVB irradiation stimulation successfully established an inflammatory model; compared with the stimulation group, the reference control group (0.01% dexamethasone) can significantly reduce the release of TNF-a; compared with the stimulation group, the experimental group (0.1% Yves-Col3-A3 or Yves-Col3-A6) can significantly reduce the release of TNF-a, indicating that Yves-Col3-A3 and Yves-Col3-A6 have anti-inflammatory effects, among which Yves-Col3-A6 has a better effect. (4) Experiment on promoting collagen synthesis in fibroblasts by recombinant type III collagen Yves-Col3
[0081] Experimental principle: Collagen content is the key to plump skin. Aging skin is often accompanied by the loss of collagen. Therefore, in anti-aging products, it is necessary to promote the synthesis of collagen to achieve the effect of plumping the skin. In this experiment, fibroblasts were incubated with collagen aqueous solutions of different concentrations and positive control TGFβ1 for 24 hours, and the ELISA experiment was used to detect the content of type I and II collagen in the cells under different treatment conditions.
[0082] The basic principle of ELISA experiment is the specificity of antigen and antibody. After the enzyme-labeled type ⅠII collagen antibody is combined with the type ⅠII collagen in the cell, the substrate of the enzyme reaction is added, and the substrate is catalyzed by the enzyme to become a colored product. The amount of the colored product is directly related to the amount of type ⅠII collagen. The OD value of the color of the colored product is detected to quantitatively analyze the type ⅠII collagen.
[0083] Experimental steps: The experimental concentration settings are shown in the following table. The culture medium in the table is FbGrowth culture medium; the ELISA kit is human type III collagen (COL3) ELISA kit.
[0084] Experimental design for promoting collagen synthesis in fibroblasts
[0085]
[0086]
[0087] 1) Cell inoculation: Collect cells in the logarithmic growth phase and set the cell density at 1×10 4 Inoculate 96-well plates with 100 μl / well incubation at 37°C and 5% CO 2 Culture in an incubator for 24 h.
[0088] 2) Sampling: Sampling is performed when the cell plating rate in the 96-well plate reaches 40% to 60%. The blank control group is inoculated with cells in the culture medium, the positive control group is inoculated with cells in the culture medium with TGFβ1 added, and the sample group is inoculated with cells in the culture medium with each concentration of diluted sample. After sampling, place the 96-well plate in an incubator (37°C, 5% CO 2 ) for 24 h.
[0089] 3) ELISA detection: After the culture is completed, the cell culture fluid is collected in a 1.5 mL centrifuge tube and then operated according to the instructions of the ELISA kit.
[0090] Positive control group type III collagen upregulation rate = (positive control group average - blank control group average) / blank control group average × 100%
[0091] The upregulation rate of type III collagen in the experimental group = (average value of the experimental group - average value of the blank control group) / average value of the blank control group × 100%
[0092] The results are as follows Figure 6 As shown, Yves-Col3-A3 and Yves-Col3-A6 can significantly upregulate the content of type III collagen and have the ability to promote the synthesis of type III collagen.
Claims
1. A recombinant type III collagen Yves-Col3 with anti-aging effects, Features Its amino acid sequence is shown in SEQ ID NO.1 or SEQ ID NO.
2.
2. The gene encoding the recombinant type III collagen Yves-Col3 according to claim 1.
3. The coding gene according to claim 2, Features Its nucleotide sequence is shown in SEQ ID NO.3 or SEQ ID NO.
4. The expression vector of the recombinant type III collagen Yves-Col3 according to claim 1 .
5. The host bacteria of the recombinant type III collagen Yves-Col3 according to claim 1.
6. The method for preparing the recombinant type III collagen Yves-Col3 according to claim 1, Features The steps include: (1) constructing the expression vector according to claim 4 and transforming it into an expression host bacterium; (2) Cultivating the expression host bacteria and inducing the expression of the recombinant protein; (3) Purify the expression product to obtain the recombinant type III collagen Yves-Col3 as claimed in claim 1.
7. Use of the recombinant type III collagen Yves-Col3 according to claim 1 in promoting cell proliferation in vitro.
8. The use according to claim 7, Features The cells are human fibroblasts.
9. Use of the recombinant type III collagen Yves-Col3 according to claim 1 in scavenging free radicals or superoxide anions in vitro.
10. Use of the recombinant type III collagen Yves-Col3 according to claim 1 in the preparation of anti-inflammatory agents.
11. Use of the recombinant type III collagen Yves-Col3 according to claim 1 in promoting the in vitro synthesis of type III collagen.
Citation Information
Patent Citations
Recombinant III-type collagen and preparation method thereof
CN116874590A
Recombinant III type collagen Pro.C3 as well as preparation method and application thereof
CN117304306A
Recombinant human-derived III-type collagen, gene, expression vector, bacterium and application of recombinant human-derived III-type collagen
CN118255873A
Recombinant type-iii collagen and method for preparing same
WO2024002149A1
Cited By
Preparation method and application of III-type recombinant collagen
CN121471343A
